HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE)
申请人:Bristol-Myers Squibb Company
公开号:EP1628974A2
公开(公告)日:2006-03-01
EP1628974A4
申请人:——
公开号:EP1628974A4
公开(公告)日:2008-05-07
US7132432B2
申请人:——
公开号:US7132432B2
公开(公告)日:2006-11-07
[EN] HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-alpha CONVERTING ENZYME (TACE)<br/>[FR] DERIVES D'HYDANTOINE EN TANT QU'INHIBITEURS DE L'ENZYME DE CONVERSION DU FACTEUR 20041216See references of EP 1628974A4
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004108086A2
公开(公告)日:2004-12-16
The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11 are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof
Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
申请人:——
公开号:US20040254231A1
公开(公告)日:2004-12-16
The present invention provides compounds of Formula (I):
1
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z
0
, R
1
, R
4
, R
5
, and R
11
are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.